OneDigital Investment Advisors LLC Has $210,000 Stock Position in ResMed Inc. (NYSE:RMD)

OneDigital Investment Advisors LLC lessened its stake in ResMed Inc. (NYSE:RMD - Free Report) by 64.0% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 920 shares of the medical equipment provider's stock after selling 1,638 shares during the period. OneDigital Investment Advisors LLC's holdings in ResMed were worth $210,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of RMD. SkyView Investment Advisors LLC grew its position in ResMed by 2.0% in the third quarter. SkyView Investment Advisors LLC now owns 2,610 shares of the medical equipment provider's stock worth $637,000 after buying an additional 51 shares during the last quarter. World Investment Advisors LLC acquired a new stake in ResMed during the third quarter valued at $541,000. Wilmington Savings Fund Society FSB acquired a new position in ResMed in the third quarter worth approximately $193,000. Tidal Investments LLC raised its holdings in shares of ResMed by 738.4% during the 3rd quarter. Tidal Investments LLC now owns 104,938 shares of the medical equipment provider's stock valued at $25,617,000 after purchasing an additional 92,422 shares in the last quarter. Finally, Franklin Resources Inc. lifted its position in shares of ResMed by 56.5% in the third quarter. Franklin Resources Inc. now owns 174,113 shares of the medical equipment provider's stock worth $41,909,000 after buying an additional 62,882 shares during the last quarter. Institutional investors and hedge funds own 54.98% of the company's stock.

Insiders Place Their Bets

In other ResMed news, Director Peter C. Farrell sold 2,000 shares of the company's stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $242.11, for a total value of $484,220.00. Following the completion of the transaction, the director now owns 77,218 shares of the company's stock, valued at $18,695,249.98. This represents a 2.52 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Michael J. Farrell sold 8,009 shares of the firm's stock in a transaction on Friday, February 7th. The shares were sold at an average price of $236.77, for a total transaction of $1,896,290.93. Following the transaction, the chief executive officer now directly owns 455,472 shares of the company's stock, valued at $107,842,105.44. The trade was a 1.73 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 49,013 shares of company stock worth $11,298,816 over the last three months. Insiders own 0.71% of the company's stock.

ResMed Trading Up 1.4 %

RMD stock traded up $3.35 during midday trading on Friday, hitting $239.84. 608,788 shares of the company's stock were exchanged, compared to its average volume of 1,006,226. The company has a market cap of $35.17 billion, a PE ratio of 28.32, a price-to-earnings-growth ratio of 1.53 and a beta of 0.75. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.29 and a current ratio of 3.33. The stock's fifty day moving average price is $222.32 and its 200-day moving average price is $233.98. ResMed Inc. has a one year low of $179.42 and a one year high of $263.05.

ResMed (NYSE:RMD - Get Free Report) last announced its earnings results on Wednesday, April 23rd. The medical equipment provider reported $2.37 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.36 by $0.01. ResMed had a return on equity of 26.17% and a net margin of 25.34%. The business had revenue of $1.29 billion for the quarter, compared to analyst estimates of $1.28 billion. During the same quarter last year, the firm earned $2.13 EPS. ResMed's revenue for the quarter was up 7.9% compared to the same quarter last year. Research analysts predict that ResMed Inc. will post 9.47 earnings per share for the current fiscal year.

ResMed Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 12th. Stockholders of record on Thursday, May 8th will be given a $0.53 dividend. This represents a $2.12 annualized dividend and a dividend yield of 0.88%. The ex-dividend date is Thursday, May 8th. ResMed's payout ratio is presently 23.79%.

Wall Street Analyst Weigh In

RMD has been the subject of several recent analyst reports. KeyCorp set a $274.00 price objective on shares of ResMed in a report on Thursday, April 24th. StockNews.com upgraded shares of ResMed from a "hold" rating to a "buy" rating in a research report on Friday. Royal Bank of Canada lifted their price objective on ResMed from $247.00 to $255.00 and gave the company a "sector perform" rating in a report on Thursday, April 24th. JPMorgan Chase & Co. boosted their target price on ResMed from $286.00 to $290.00 and gave the stock an "overweight" rating in a report on Thursday, April 24th. Finally, The Goldman Sachs Group initiated coverage on shares of ResMed in a research report on Thursday, January 16th. They issued a "buy" rating for the company. One investment analyst has rated the stock with a sell rating, five have given a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $258.83.

ResMed Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.